This includes its two clinical-stage CD19-targeting allogeneic CAR T candidates, PBCAR0191 and PBCAR19B stealth cell, as well as four additional product targets. The development of the candidates leveraged Precision's Arcus genome editing platform.

Under the terms, Servier will receive $1.3 million in cash and Precision has agreed to waive earned, but as-yet unpaid, milestones totaling $18.8 million that would have otherwise been payable to Precision. Servier is also eligible to receive milestones and low- to mid-single-digit royalties subject to product development achievement. With respect to products directed to CD19, Servier has certain rights of negotiation if Precision elects to repartner the programs.

By the end of May 2021, Precision expects to dose the first patient with PBCAR19B, its second CD19 allogeneic CAR T candidate that is engineered with Precision's proprietary stealth cell technology.